Scienture (NASDAQ:SCNX) Stock Rating Lowered by Wall Street Zen

Scienture (NASDAQ:SCNX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scienture in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Scienture Stock Performance

NASDAQ:SCNX opened at $0.48 on Friday. Scienture has a 52 week low of $0.46 and a 52 week high of $4.40. The firm has a 50-day moving average price of $0.55 and a two-hundred day moving average price of $0.96. The firm has a market cap of $19.53 million, a price-to-earnings ratio of -0.48 and a beta of 3.00.

Scienture (NASDAQ:SCNX) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.19) EPS for the quarter. The firm had revenue of $0.59 million during the quarter.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.